Not yet recruitingPHASE1, PHASE2NCT07297875

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Studying Achondroplasia

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Abbisko Therapeutics Co, Ltd
Principal Investigator: Shuqi Zeng
12B, Building 1, No 515, Huanke Road, Pudong New Area, Shanghai 201210, China
Intervention: ABSK061(drug)
Enrollment: 110 enrolled
Eligibility: 3-12 years · All sexes
Timeline: 2025 – 2031

Study locations (7)

Beijing Children's Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Chengdu Women's and Children's Central Hospital, Chengde, Sichuan, China
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07297875 on ClinicalTrials.gov

Other trials for Achondroplasia

Additional recruiting or active studies for the same condition.

See all trials for Achondroplasia →

← Back to all trials